Press releases
Browse US-specific press releases here.
Please visit our Global website for access to global press releases dating back to 2009.
-
Jemperli (dostarlimab-gxly) receives US FDA Breakthrough Therapy Designation for locally advanced dMMR/MSI-H rectal cancer
Designation based on data showing no evidence of disease in 100% of all 42 patients who completed treatment with dostarlimab-gxly.
Download (PDF, 306.5KB) -
Belantamab Mafodotin shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapse
DREAMM-7 trial shows sustained overall survival benefit for belantamab mafodotin combination versus daratumumab combination.
Download (PDF, 235.3KB) -
US FDA accepts GSK’s submission for the use of Nucala (mepolizumab) in COPD
Nucala could be the first approved biologic with monthly dosing for patients with COPD
Download (PDF, 206.4KB) -
Belantamab mafodotin combinations accepted for review by the US FDA for the treatment of relapsed/refractory multiple myeloma
Regulatory submission supported by phase III head-to-head DREAMM-7 and DREAMM-8 trials showing statistically significant efficacy.
Download (PDF, 150.9KB) -
GSK Celebrates 2024 IMPACT Award Winners
Investments now totaling nearly $16.5M to improve health in the Triangle (North Carolina) and Greater Philadelphia regions.
Download (PDF, 163.6KB) -
GSK invests up to $800 million in Pennsylvania site, largest manufacturing investment in U.S.
GSK is outfitting its Marietta, Pennsylvania, site with new state-of-the-art facilities dedicated to producing medicines and vaccines.
Download (PDF, 128.1KB) -
New data for AREXVY, GSK’s respiratory syncytial virus vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease
Single dose of vaccine elicited robust immune response with acceptable safety profile in adults aged 18-49 at increased risk for RSV-LRTD.
Download (PDF, 271.2KB) -
ViiV Healthcare shows more than 99% effectiveness in real-world studies for Apretude (cabotegravir long-acting), the only approved long-acting HIV PrEP, in data presented at IDWeek 2024
Studies from OPERA and Trio cohorts provide further real-world evidence.
Download (PDF, 271.8KB) -
Gepotidacin accepted for priority review by US FDA for treatment of uncomplicated urinary tract infections in female adults and adolescents
Application supported by positive results from pivotal phase III EAGLE-2 and EAGLE-3 trials
Download (PDF, 133.0KB) -
GSK and ViiV Healthcare to showcase advances across industry-leading infectious disease portfolio at IDWeek 2024
60 abstracts to be presented across broad and growing portfolio of vaccines and medicines aimed at getting ahead of infectious disease.
Download (PDF, 314.0KB) -
Statement: Zantac (ranitidine) litigation – settlement agreements reached
GSK to resolve 93% (approximately 80,000 cases) of U.S. state court Zantac product liability cases for up to $2.2 billion.
Download (PDF, 130.6KB) -
GSK presents positive data for AREXVY, its respiratory syncytial virus (RSV) vaccine, indicating protection over three RSV seasons
GSK will continue to provide data on longer-term follow-up to help recommending bodies determine future revaccination schedules
Download (PDF, 274.3KB) -
Statement: Zantac litigation – Joiner case
Jury in Joiner case in Illinois state court finds GSK not liable for plaintiff’s colorectal cancer
Download (PDF, 126.9KB) -
US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit
Jemperli approval now includes MMRp/MSS tumors, which represent majority of endometrial cancer cases.
Download (PDF, 318.6KB) -
Summer Will Be Out of This World for Philly-Area Students with GSK Science in the Summer™ & the Science of Space
Free STEM program returns to local libraries this summer for the 32nd year. Online registration begins in May 2018.
-
GSK presents new efficacy data for FLUARIX® QUADRIVALENT (Influenza Vaccine) in children 6 months through 35 months of age
GSK presented today at the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices
-
Sensodyne® Rapid Relief Launches in the United States
New toothpaste provides clinically-proven relief from tooth sensitivity in just three days
-
Summer Will Be Out of This World for Elementary School Students with GSK Science in the Summer™ and the Science of Space
Free STEM program returns to libraries and community centers across the country
-
Local nonprofits make a bigger IMPACT with $40,000 award from GSK in Greater Philadelphia region
GSK and The Philadelphia Foundation today issued the call for applications for the 2018 GSK IMPACT Awards.
